UroToday.com) The Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting held in Toronto, ON between June 8th and June 11th, 2024 was host to a prostate cancer therapy session. Dr. Fuad Novruzov presented the results of a prospective phase 3 randomized study from Azerbaijan evaluating 225Ac-PSMA + 177Lu-PSMA tandem therapy for metastatic castration-resistant prostate cancer (mCRPC).
While 225Ac-PSMA has demonstrated promising therapeutic efficacy in heavily pre-treated mCRPC patients, there are still some concerns regarding its safety profile and toxicity for organs at risk.1 Combining the alpha emitter 225Ac with the beta emitter 177Lu as tandem therapy at reduced doses may reduce the adverse effects of alpha emitters, while potentially increasing the therapeutic efficacy of beta emitters alone. The objective of this study was to present preliminary findings from a phase 3, single-center, prospective, randomized, two-arm controlled study evaluating 225Ac-PSMA + 177Lu-PSMA tandem therapy for mCRPC patients.
Patients with androgen receptor pathway inhibitor (ARPI) and docetaxel pre-treated mCRPC who exhibited high uptake on PSMA PET were randomized to 225-Actinium / 177- Lutetium labeled PSMA (PSMA tandem treatment) versus the current standard-of-care with docetaxel. The study inclusion criteria were as follows:
source
My experience and my thoughts about undergoing radioligand therapy using the PSMA-617 ligand loaded with 177Lu and 225Ac isotopes. Part 1.
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide.
